| Over a week ago | ||||
Citi analyst Peter… Citi analyst Peter Verdult reiterated a Buy rating and GBp 3,030 price target on Hikma Pharmaceuticals (HKMPF), saying that November Iqvia (IQV) data points to trends towards, and above, the upper end of fiscal 2020 guidance. The analyst added that underlying trends point to upside risks. | ||||
Hikma Pharmaceuticals… Hikma Pharmaceuticals (HKMPF) announced it has received FDA approval for and launched its generic version of GlaxoSmithKline's (GSK) Advair Diskus, 100mcg/50mcg and 250mcg/50mcg doses in the U.S. According to IQVIA, U.S. sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg/50mcg and 250mcg/50mcg, were approximately $2B in the 12 months ending September 2020. | ||||
| Over a month ago | ||||
JPMorgan analyst James… JPMorgan analyst James Gordon raised the firm's price target on Hikma Pharmaceuticals to 3,000 GBp from 2,400 GBp and keeps an Overweight rating on the shares. | ||||
Hikma Pharmaceuticals… Hikma Pharmaceuticals (HKMPF) has launched Icosapent Ethyl Capsules, 1gm, in the US through its US affiliate, Hikma Pharmaceuticals USA Inc. Following an earlier than expected favorable court ruling, Hikma has accelerated the launch of its Icosapent Ethyl Capsules in order to quickly provide patients with access to this important medicine. Initially, Hikma will be releasing limited quantities to ensure a consistent supply for customers. The company is working to scale up manufacturing and increase availability as soon as possible. "Hikma's launch of this important medicine for US patients and healthcare providers once again underscores our ability to put better health, within reach, every day for millions of people who rely on our medicines," said Brian Hoffmann, President of Hikma Generics. "Today's launch demonstrates Hikma's ability to successfully challenge patents and launch complex products, bringing greater value to our customers and patients." Hikma's product is not approved for any other indication for the reference listed drug VASCEPA (AMRN). | ||||
| Over a quarter ago | ||||
Morgan Stanley analyst… Morgan Stanley analyst Thibault Boutherin downgraded Hikma Pharmaceuticals to Equal Weight from Overweight with a price target of 2,600 GBp, down from 2,700 GBp, noting that expectations for Hikma have been raised. | ||||
Morgan Stanley analyst… Morgan Stanley analyst Thibault Boutherin downgraded Hikma Pharmaceuticals to Equal Weight from Overweight with a 2,700 GBp price target. | |
Goldman Sachs analyst… Goldman Sachs analyst Krishna Arikatla upgraded Hikma Pharmaceuticals to Buy from Neutral with a price target of 3,115 GBp, up from 2,600 GBp. Hikma shares can continue to outperform, as potential launches of Advair and Vascepa provide upside risk to consensus estimates, Arikatla tells investors in a research note. The analyst believes consensus estimates are underappreciating the bottom line contribution from these two launches, especially for Advair. | |
Goldman Sachs analyst… Goldman Sachs analyst Paul Choi lowered the firm's price target on Amarin (AMRN) to $8 from $9 and keeps a Neutral rating on the shares after reducing expectations for sales of Vascepa to reflect the court's negative appeal decision. The analyst expects at least one generic product to be launched imminently, potentially as soon as year-end. Hikma Pharmaceuticals (HKMPF) management has disclosed that they are comfortable with their ability to ramp supply and to initiate a launch following the court's decision, Choi tells investors in a research note. While it remains to be seen how Amarin will contend with the entry of generics products into the market, management recently emphasized its willingness to compete on price, adds the analyst. Choi, however, continues to view the market opportunity for Vascepa in Europe as "significant" at $1.3B in peak sales, and he expects investor focus to now shift to Amarin's opportunities outside the U.S. | |
Barclays analyst Emily… Barclays analyst Emily Field upgraded Hikma Pharmaceuticals to Overweight from Equal Weight with a 2,800 GBp price target. The analyst has a high degree of confidence in adding Vascepa to the model following yesterday's court ruling. The decision on Vascepa came well ahead of schedule and the product should be significantly accretive for 2020 and 2021 earnings, Field tells investors in a research note. | |